Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.
CareDx, Inc. is holding its 2026 annual stockholders meeting virtually on June 11, 2026, to vote on key governance and compensation matters. Stockholders will elect five directors, ratify Deloitte & Touche LLP as auditor, approve executive pay on an advisory basis, and choose the frequency of future say‑on‑pay votes, with the Board recommending an annual vote.
They will also vote on amending the 2024 Equity Incentive Plan to increase shares reserved for equity awards. The record date is April 15, 2026, covering 51,547,801 common shares. The Board is majority independent, operates four committees, has stock ownership guidelines for directors and executives, a clawback policy, and paid Deloitte $2.43 million in 2025 audit-related fees.
CareDx, Inc. updated the compensation details for Keith Kennedy, who serves as both Chief Financial Officer and Chief Operating Officer. In recognition of his expanded responsibilities, the board’s Compensation and Human Capital Committee granted him new equity awards.
Kennedy received 24,134 restricted stock units (RSUs), with one-third vesting on April 6, 2027 and the remainder vesting quarterly thereafter, subject to continued service. He was also awarded 24,134 performance-based RSUs (PRSUs), which may vest between 0% and 200% of the target amount based on performance over the 2026 and 2027 periods and additional time-based vesting. These grants are under the company’s 2024 Equity Incentive Plan, and his $613,000 annual base salary and 75% target bonus opportunity remain unchanged.
Kennedy Keith reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. CFO & COO Keith Kennedy received a grant of 24,134 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share. After this award, he directly holds 221,548 shares.
According to the terms, one-third of these RSUs will vest on April 6, 2027. The remaining two-thirds will vest in equal quarterly installments over the next eight quarters, so that all units vest by the third anniversary of April 6, 2027, if his employment continues through each vesting date.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of Common Stock. On April 16, he sold 10,282 shares at $21.12 per share in a single transaction. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on December 13, 2024, and he continues to own 676,475 shares directly after the transaction.
CDNA disclosed proposed sales of common stock via a Rule 144 notice. The submission lists 10,282 shares associated with restricted stock units dated 04/15/2025 and shows recent 10b5-1 sales by John Hanna of 19,280 and 200 shares on 01/22/2026 and 01/21/2026, respectively.
CareDx, Inc.'s President and CEO John Walter Hanna Jr. reported a routine tax-related share disposition. On the vesting of restricted stock units, 62,049 shares of common stock were withheld by the company at $17.57 per share to cover tax obligations. After this withholding, he continues to hold 686,757 common shares directly, indicating he retains a substantial equity position in the company.
CareDx, Inc. entered a definitive agreement to sell its Lab Products business, including Swedish subsidiary CareDx AB and related software assets, to Eurobio Scientific for $170 million in cash, subject to customary working capital and other adjustments.
The transaction is intended to sharpen CareDx’s focus on its core U.S.-based Precision Medicine Testing Services and Patient and Digital Solutions, simplify its operating model, and support AEBITDA margin expansion. Closing is subject to customary conditions, including Swedish regulatory review, and is targeted by the end of CareDx’s third quarter 2026.
CareDx expects to allocate proceeds using a disciplined capital approach, prioritizing growth investments aligned with its Precision Diagnostics Solutions model and potentially returning capital to shareholders. For the first quarter of 2026, the company reports preliminary testing services revenue growth of approximately 48% year over year, testing volume growth of about 17%, and Patient and Digital Solutions revenue growth of roughly 33%.